Clinical trials
Unresectable Metastatic Colorectal Cancer clinical trials
Below are recruiting unresectable metastatic colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 198 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07805551RecruitingPhase 1/Phase 2
HDM2017 combination therapy for advanced colorectal cancer
This study tests a new drug called HDM2017 in combination with other treatments for advanced colorectal cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06497985RecruitingPhase 3
New drug combo for advanced colorectal cancer
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
Guangzhou, GuangdongAges 18–75 - NCT07558083RecruitingPhase 3
Tracking colorectal cancer response using blood tests
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
Mechelen, AntwerpenAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT07604909RecruitingPhase 2
Serplulimab plus chemotherapy for early-relapsed colorectal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
ShanghaiAges 18 years+ - NCT07527858RecruitingPhase 2
Study of Denikitug with immunotherapy or chemotherapy for advanced colorectal cancer
This trial tests a new drug called denikitug, given alone or combined with other cancer treatments, for patients with advanced colorectal cancer that hasn't responded to previous treatments. The goal is to help people whose cancer has a specific genetic profile (MSS) that doesn't respond well to standard immunotherapy alone.
North Haven, ConnecticutAges 18 years+ - NCT07044908RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75 - NCT07204574RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer after first treatment
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
TaoyuanAges 18 years+ - NCT07201519RecruitingPhase 2
Chemo infusion for liver cancer using a hybrid care model
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Lexington, KentuckyAges 18–99 - NCT07001085Recruiting
Blood test to monitor liver cancer after surgery
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Warsaw, Masovian VoivodeshipAges 18–75 - NCT06808685Recruiting
Study of Elovie for advanced colorectal cancer
This study looks at how well a biosimilar version of bevacizumab (Elovie) works in people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if Elovie is safe and effective when used as the first treatment for this cancer.
Vitória, Espírito SantoAges 18 years+ - NCT05787197Recruiting
Blood test to guide treatment after colon cancer liver surgery
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
BesançonAges 18 years+ - NCT06434597RecruitingPhase 2
Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
BeijingAges 18 years+ - NCT06403735RecruitingPhase 1
Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Guangzhou, GuangdongAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT06722183RecruitingPhase 2
Futibatinib plus chemo-immunotherapy for advanced colorectal cancer
This trial tests a new combination of drugs (futibatinib plus chemo-immunotherapy) for people with advanced colorectal cancer who have not had prior treatment. It aims to see if this combination can shrink tumors or slow their growth.
AmbergAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable metastatic colorectal cancer?
- Yes. Clin2 currently lists 198 recruiting unresectable metastatic colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable metastatic colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.